AMANDA SNOW: Open Payments
NPI 1639640063 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,033 in 162 payments from 20 companies in 2025. Trend: 2023 $3,178 · 2024 $3,405 · 2025 $3,033
Food & beverage: $2,918Education: $115
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 23 | $544 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $268 |
| Axsome Therapeutics, Inc. | 13 | $260 |
| Alkermes, Inc. | 17 | $246 |
| Vanda Pharmaceuticals Inc. | 8 | $219 |
| Teva Pharmaceuticals USA, Inc. | 8 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $191 |
| Lundbeck LLC | 17 | $188 |
| Janssen Pharmaceuticals, Inc | 9 | $184 |
| Supernus Pharmaceuticals, Inc. | 11 | $158 |
Products named: COBENFY, CAPLYTA, Auvelity, ARISTADA, FANAPT, REXULTI, TRINTELLIX, Qelbree.
Industry payments across VA — which companies pay providers there.
